IRIS
CESARO, ARTURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 894
NA - Nord America 816
AS - Asia 205
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.925
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 815
IE - Irlanda 488
IT - Italia 134
GB - Regno Unito 90
SG - Singapore 82
CN - Cina 81
DE - Germania 61
GR - Grecia 25
FR - Francia 21
UA - Ucraina 18
SE - Svezia 17
BE - Belgio 12
FI - Finlandia 11
KR - Corea 11
TR - Turchia 10
IN - India 9
AR - Argentina 4
ES - Italia 4
NL - Olanda 4
DK - Danimarca 3
TW - Taiwan 3
VE - Venezuela 3
EU - Europa 2
ID - Indonesia 2
IR - Iran 2
RU - Federazione Russa 2
VN - Vietnam 2
AT - Austria 1
CA - Canada 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
HK - Hong Kong 1
IL - Israele 1
JP - Giappone 1
PL - Polonia 1
RO - Romania 1
Totale 1.925
Salva come PNG Salva come JPEG
Città #
Dublin 481
Chandler 241
New York 96
Singapore 55
Princeton 52
Roxbury 52
Jacksonville 37
Bremen 35
Cambridge 31
Naples 30
Beijing 26
Des Moines 23
Medford 23
Boardman 15
Ann Arbor 12
Brussels 12
Seoul 11
Wilmington 11
Nanjing 8
Sivas 8
Caserta 7
Hyderabad 7
Milan 7
Ashburn 6
Lappeenranta 6
Helsinki 5
Salerno 5
Bresso 4
Houston 4
Jinan 4
Shenyang 4
Woodbridge 4
Casier 3
Duncan 3
Fairfield 3
Juelsminde 3
Los Angeles 3
Xi'an 3
Amsterdam 2
Andover 2
Camden 2
Castenaso 2
Catamarca 2
Chiayi County 2
Cipolletti 2
Dong Ket 2
Genoa 2
Grafing 2
Groningen 2
Guangzhou 2
Hanover 2
Hebei 2
Malang 2
Mountain View 2
Norwalk 2
Padova 2
Paris 2
Philadelphia 2
Piombino 2
Pune 2
San Giovanni In Fiore 2
San Giuliano Terme 2
San Mateo 2
San Nicola la Strada 2
Seattle 2
Somma Vesuviana 2
St Petersburg 2
Bacau 1
Bari 1
Brdo 1
Brunswick 1
Canterbury 1
Castrovillari 1
Chicago 1
Créteil 1
Giussano 1
Hamm 1
Hangzhou 1
Hong Kong 1
Jerusalem 1
Jiaxing 1
Kraków 1
Laurel 1
Livorno 1
Maddaloni 1
Madrid 1
Montecchio Maggiore 1
Munich 1
Nanchang 1
Napoli 1
Orta di Atella 1
Palena 1
Pensacola 1
Pievepelago 1
Quito 1
Recale 1
Rome 1
Sant'angelo D'alife 1
Schio 1
Selargius 1
Totale 1.431
Salva come PNG Salva come JPEG
Nome #
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 59
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 57
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 56
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 53
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 52
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 51
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 47
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 45
Childhood obesity: An overview of laboratory medicine, exercise and microbiome 45
Advanced Heart Failure in Special Population—Pediatric Age 44
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 43
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 42
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 42
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 42
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 41
Diagnosis and Management of Cardiovascular Involvement in Fabry Disease 40
Early-onset MINOCA: Prognostic implications and considerations for practice 40
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 39
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 39
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 36
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 36
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 35
Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge 34
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 34
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 33
Coronary stent thickness: thinner is (always) better for all lesions? 33
Cardiac involvement in systemic sclerosis: 'early diagnosis-early management' approach 32
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 32
SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction 31
Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT) 30
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 30
The Biological Role of Vitamins in Athletes’ Muscle, Heart and Microbiota 30
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 29
Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): A meta-analysis 29
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 28
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 27
Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis? 26
SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes 26
Left atrial and auricular thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 23
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 23
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 23
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 23
Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve 23
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry 23
Laboratory medicine: health evaluation in elite athletes 22
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 21
Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism 20
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 20
Multimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter 20
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 20
Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent 19
Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease 19
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey 19
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 18
[Long COVID: nosographic aspects and clinical epidemiology] 17
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study 16
Rheumatic mitral stenosis in a 28-week pregnant woman treated by mitral valvuoplasty guided by low dose of radiation: a case report and brief overview 16
Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis 16
Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target 15
Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein? 14
Multimodality Imaging in Arrhythmogenic Left Ventricular Cardiomyopathy 14
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 13
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 13
The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review 12
Geographic variations in percutaneous versus surgical coronary revascularization: A global perspective from the SYNTAXES trial 11
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 11
Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology 11
Reply to SGLT-2 inhibitors: Post-infarction interventional effects 10
Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention 10
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 10
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 10
The Role of Genetic Testing in Patients with Heritable Thoracic Aortic Diseases 10
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes 10
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology 9
How has COVID-19 impacted the care of patients with acute coronary syndromes? 8
The Impact of Physical Exercise on Obesity in a Cohort of Southern Italian Obese Children: Improvement in Cardiovascular Risk and Immune System Biomarkers 8
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque 7
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry 7
The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia 7
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 7
Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention 5
Evolving concepts in the pathophysiology of atherosclerosis: from endothelial dysfunction to thrombus formation through multiple shades of inflammation 5
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 5
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 5
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go 4
Secondary Prevention and Extreme Cardiovascular Risk Evaluation (SEVERE-1), Focus on Prevalence and Associated Risk Factors: The Study Protocol 3
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 2
Totale 2.125
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.348
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.348
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202039 0 0 0 0 5 1 11 5 7 5 5 0
2020/2021148 3 0 3 24 21 0 34 2 11 7 30 13
2021/2022436 9 3 8 17 106 10 10 41 9 56 38 129
2022/2023879 85 57 20 59 79 47 2 58 436 5 15 16
2023/2024522 28 17 21 25 132 113 19 12 5 29 13 108
2024/202524 8 14 2 0 0 0 0 0 0 0 0 0
Totale 2.125